INSEMA and SOUND are among four trials designed to evaluate omission of SLNB in patients with clinically node-negative early ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

Daiichi Sankyo plans ADC facility in Shanghai, BioMarin expands in Cork, Vertex signs Saudi deal, EuroAPI CEO resigns, SK ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Daiichi Sankyo invests $150 million to establish a new antibody-drug conjugate manufacturing facility in Shanghai by 2030, ...

Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million ...

Project EVOLVE, funded by Daiichi Sankyo and AstraZeneca, to be presented at the 2024 San Antonio Breast Cancer Symposium -- NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Novellia, Inc., an AI-enabled ...

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...